Halozyme Therapeutics

Halozyme Therapeutics

Yahoo Finance • 2 days ago

1 Healthcare Stock with Exciting Potential and 2 We Avoid

1 Healthcare Stock with Exciting Potential and 2 We Avoid Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as h... Full story

Yahoo Finance • 5 days ago

Biotech Breakout: What's in focus after Moderna's cancer win?

[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [htt... Full story

Yahoo Finance • 5 days ago

2 Mid-Cap Stocks with Solid Fundamentals and 1 Facing Challenges

2 Mid-Cap Stocks with Solid Fundamentals and 1 Facing Challenges Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face i... Full story

Yahoo Finance • 10 days ago

XBI vs. FBT: Broad Biotech Exposure or Concentrated Bets?

The State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) provides broad exposure to the biotech industry, while the First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) offers a much more concentrated, equal-weighted alternative. Biote... Full story

Yahoo Finance • 19 days ago

Biotech Stocks At 52-Week Highs - HALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE

(RTTNews) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming clinical results. Halozyme Therapeutics Inc. (HALO) Halozyme is a biopharmaceutical... Full story

Yahoo Finance • last month

State Street vs. First Trust: Is a Broad Healthcare or Biotech Focus Better for Your Portfolio?

Key Points State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio of 0.08% compared to the 0.55% charged by First Trust NYSE Arca Biotechnology Index Fund. First Trust's fund focuses exclusively on 30 b... Full story

Yahoo Finance • last month

Four Stocks Hit New Highs Amid Tech Meltdown

Halozyme Therapeutics is at a new high on Friday with earnings due on Aug. 6. Philip Morris International and KeyCorp are also at highs. Continue Reading... Full story

Yahoo Finance • last month

Halozyme in deal with Incyte to use Enhanze technology for neoplasms candidate

[Businessmen shaking hands] Andy Andrews * Halozyme (HALO [https://seekingalpha.com/symbol/HALO]) has signed a global collaboration and license agreement with Incyte (INCY [https://seekingalpha.com/symbol/INCY]) to potentially use the f... Full story

Yahoo Finance • 2 months ago

2 Reasons to Like HALO and 1 to Stay Skeptical

2 Reasons to Like HALO and 1 to Stay Skeptical Halozyme Therapeutics trades at $78.57 and has moved in lockstep with the market. Its shares have returned 8.5% over the last six months while the S&P 500 has gained 7.2%. Is now the time to... Full story

Yahoo Finance • 2 months ago

Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks

Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let's have a look at AbbVie (NYSE:ABBV) and its p... Full story

Yahoo Finance • 2 months ago

Halozyme Appoints David Ramsay as President Drug Delivery

SAN DIEGO, June 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the appointment of David Ramsay as President Drug Delivery, effective June 30, 2026. In this newly created r... Full story

Yahoo Finance • 3 months ago

How New ENHANZE Data And Analyst Support At Halozyme Therapeutics (HALO) Has Changed Its Investment Story

In recent days, Halozyme Therapeutics’ partner argenx reported positive new data for a therapy using Halozyme’s ENHANZE® drug delivery technology, while an analyst reaffirmed a positive rating on the company. This combination of external c... Full story

Yahoo Finance • 3 months ago

JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms

Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commer... Full story

Yahoo Finance • 3 months ago

One of the market's hottest stock themes is buying everything AI can't replace

As investors worry about all of the companies that AI will wipe out, they are rotating into the ones that AI will have a harder time disrupting. And the HALO trade, as it is called, is working. HALO, which stands for "heavy assets, low ob... Full story

Yahoo Finance • 4 months ago

After-Hours Earnings Report for May 11, 2026 : SPG, ASTS, STE, OVV, ACM, HALO, SGHC, HIMS, RGTI, IFS, NOVT, MARA

The following companies are expected to report earnings after hours on 05/11/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Simon Property Group, Inc. (SPG)is reporting for the quarter ending March 31,... Full story

Yahoo Finance • 4 months ago

A Look At Halozyme Therapeutics (HALO) Valuation After Recent Share Price Swings

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Halozyme Therapeutics (HALO) is back on investors’ radar after rec... Full story

Yahoo Finance • 4 months ago

Stocks Finish Higher on Solid Earnings and a Resilient Labor Market

The S&P 500 Index ($SPX) (SPY) on Friday closed up +0.84%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.02%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +2.35%.  June E-mini S&P futures (ESM26) rose +0.79%, and June E-m... Full story

Yahoo Finance • 4 months ago

Halozyme (HALO) Rated Buy on Strong Royalty Growth

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the most profitable biotech stocks to buy now. On April 13, TD Cowen reaffirmed its Buy rating and $96 price target for Halozyme Therapeutics, Inc. (NASDAQ:HALO). The firm forecasts Hal... Full story

Yahoo Finance • 4 months ago

How Investors Are Reacting To Halozyme Therapeutics (HALO) Hiring Big-Pharma Veteran Darren Snellgrove As CFO

Halozyme Therapeutics recently announced that Darren Snellgrove, a veteran finance leader with more than 30 years of biopharma experience including senior roles at Johnson & Johnson, will become its Chief Financial Officer on June 8, 2026,... Full story

Yahoo Finance • 4 months ago

Spotting Winners: AbbVie (NYSE:ABBV) And Therapeutics Stocks In Q4

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie (NYSE:ABBV). Over the next few years, therap... Full story